Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

被引:8
|
作者
Nyga, Mari [1 ,11 ]
Engesaeter, Birgit [1 ]
Castle, Philip E. [2 ,3 ]
Berland, Jannicke Mohr [4 ]
Eide, Maj Liv [5 ]
Iversen, Ole Erik [6 ,7 ]
Jonassen, Christine Monceyron [8 ]
Christiansen, Irene Kraus [9 ]
Vintermyr, Olav Karsten [7 ,10 ]
Trope, Ameli [1 ]
机构
[1] Canc Registry Norway, Oslo, Norway
[2] NCI, Div Canc Prevent, NIH, Rockville, MD USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Stavanger Univ Hosp, Stavanger, Rogaland, Norway
[5] Trondheim Reg & Univ Hosp, Trondheim, Norway
[6] Univ Bergen, Inst Clin Sci, Bergen, Norway
[7] Haukeland Hosp, Bergen, Norway
[8] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[9] Akershus Univ Hosp, Lorenskog, Norway
[10] Univ Bergen, Gades Lab Pathol, Bergen, Norway
[11] Canc Reg istry Norway, Res Dept, Postbox Majorstuen 5313, N-0304 Oslo, Norway
关键词
INTRAEPITHELIAL NEOPLASIA; FOLLOW-UP; CYTOLOGY; RISK; PREVENTION; TRIAGE;
D O I
10.1158/1055-9965.EPI-22-0340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technol-ogy transfer within the nationwide screening programme in Nor-way, HPV-Screening protocol was implemented randomized to compare the real-world effectiveness of HPV-Screening protocol and LBC-Screening protocol at the first screening round. Methods: Among 302,295 women ages 34 to 69 years scheduled to attend screening from February 2015 to June 2017, 157,447 attended. A total of 77,207 were randomly allocated to the HPV-Screening protocol and 80,240 were allocated to the LBC-Screening protocol. All women were followed up for 18 months. Results: The HPV-Screening protocol resulted in a relative increase of 60% in the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse [risk ratio (RR) = 1.6, 95% confidence interval (CI) = 1.5-1.7], 40% in CIN grade 3 or worse (RR = 1.4, 95% CI = 1.3-1.6), 40% in cancer (RR = 1.4, 95% CI = 1.0-2.1), and 60% in colposcopy referrals (RR = 1.6, 95% CI = 1.5-1.6) compared with LBC-Screening. The perfor-mance of both protocols was age dependent, being more effective in women ages under 50 years. Conclusions: The HPV-Screening protocol was well accepted by women in Norway and detected more CIN2, CIN3, and cancers compared with the LBC-Screening protocol.Impact: A randomized implementation of the HPV-Screening protocol with real-world assessment enabled a gradual, quality assured, and safe technology transition. HPV-based screening protocol may further be improved by using HPV genotyping and age-specific referral algorithms.
引用
收藏
页码:1812 / 1822
页数:11
相关论文
共 50 条
  • [41] Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience - Reply
    Agorastos, Theodoros
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 1169 - 1170
  • [42] Cervical cancer prevention and screening: the role of human papillomavirus testing
    Aref-Adib, Mehrnoosh
    Freeman-Wang, Theresa
    [J]. OBSTETRICIAN & GYNAECOLOGIST, 2016, 18 (04): : 251 - 263
  • [43] Cervical Cancer Screening in the Era of Human Papillomavirus Testing and Vaccination
    Murphy, Jeanne
    Mark, Hayley
    [J]. JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2012, 57 (06) : 569 - 576
  • [44] Practice Patterns in Cervical Cancer Screening and Human Papillomavirus Testing
    Tatsas, Amanda D.
    Phelan, Darcy F.
    Gravitt, Patti E.
    Boitnott, John K.
    Clark, Douglas P.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (02) : 223 - 229
  • [45] Utility of Human Papillomavirus Testing for Cervical Cancer Screening in Korea
    Kim, Mee-seon
    Lee, Eun Hee
    Park, Moon-il
    Lee, Jae Seok
    Kim, Kisu
    Roh, Mee Sook
    Lee, Hyoun Wook
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (05)
  • [47] Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador
    Alfaro, Karla
    Maza, Mauricio
    Felix, Juan C.
    Gage, Julia C.
    Castle, Philip E.
    Alonzo, Todd A.
    Chacon, Andrea
    Gonzalez, Enrique
    Soler, Montserrat
    Conzuelo-Rodriguez, Gabriel
    Masch, Rachel
    Cremer, Miriam
    [J]. JCO GLOBAL ONCOLOGY, 2020, 6 : 1519 - 1530
  • [48] Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania
    Cooper, Emma C.
    Maher, Justine A.
    Naaseh, Ariana
    Crawford, Elizabeth W.
    Chinn, Justine O.
    Runge, Ava S.
    Lucas, Alexa N.
    Zezoff, Danielle C.
    Bera, Kevin R.
    Dinicu, Andreea I.
    White, Kayla M.
    Tewari, Sujata E.
    Hari, Anjali
    Bernstein, Megan
    Chang, Jenny
    Ziogas, Argyrios
    Pearre, Diana C.
    Tewari, Krishnansu S.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (01)
  • [49] Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management
    Cox, J. Thomas
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2006, 61 : S15 - S25
  • [50] The value of human papillomavirus detection in primary cervical cancer screening
    Baay, MFD
    Weyler, J
    Vermorken, JB
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2004, 25 (06) : 665 - 669